Genmab A/S
CSE:GMAB
Genmab A/S
Long-Term Debt
Genmab A/S
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Genmab A/S
CSE:GMAB
|
Long-Term Debt
kr937m
|
CAGR 3-Years
37%
|
CAGR 5-Years
43%
|
CAGR 10-Years
N/A
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Long-Term Debt
kr375.7m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
37%
|
CAGR 10-Years
3%
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Long-Term Debt
€365.1m
|
CAGR 3-Years
55%
|
CAGR 5-Years
64%
|
CAGR 10-Years
N/A
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Long-Term Debt
kr86.7m
|
CAGR 3-Years
-68%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
10%
|
|
|
Bioporto A/S
CSE:BIOPOR
|
Long-Term Debt
kr7.8m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
38%
|
CAGR 10-Years
56%
|
|
|
Saniona AB
STO:SANION
|
Long-Term Debt
kr0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Genmab A/S
Glance View
In the world of biotechnology, Genmab A/S has carved a niche as a leader in the development and innovation of antibody therapeutics. Established in Denmark in 1999, the company has focused on harnessing the power of antibodies to create novel treatments for cancer and other serious diseases. Genmab's approach is both scientific and strategic, leveraging its proprietary DuoBody and HexaBody platforms to engineer antibodies that are designed to enhance effectiveness and reduce side effects. This innovative focus has not only set Genmab apart as a pioneer in immunotherapy but has also yielded a rich pipeline of products, several of which have gained regulatory approval and found a place in global markets. Genmab's business model is built on a foundation of collaboration and strategic partnerships with major pharmaceutical companies, including heavyweights such as Janssen and Roche. These alliances are crucial as they provide the financial support needed for large-scale clinical trials and access to global distribution networks. Revenue streams primarily flow from milestone payments, licensing fees, and royalties generated from successful therapies. The company's notable blockbuster, Darzalex, a treatment for multiple myeloma, continues to be a significant revenue driver, exemplifying Genmab's capacity to transform scientific discovery into economic success. Through this blend of innovation, strategic partnerships, and commercialization, Genmab maintains a robust business while keeping its dedication to pioneering treatments at the forefront of its mission.
See Also
What is Genmab A/S's Long-Term Debt?
Long-Term Debt
937m
DKK
Based on the financial report for Dec 31, 2024, Genmab A/S's Long-Term Debt amounts to 937m DKK.
What is Genmab A/S's Long-Term Debt growth rate?
Long-Term Debt CAGR 5Y
43%
Over the last year, the Long-Term Debt growth was 38%. The average annual Long-Term Debt growth rates for Genmab A/S have been 37% over the past three years , 43% over the past five years .
You don't have any saved screeners yet